Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Multiple Dose Study of Usnoflast (ZYIL1) in Healthy Adults
NCT04972188Phase 1Completed
- Sponsor
- Zydus Lifesciences Limited
- Start
- Jul 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of usnoflast in coronavirus disease 2019 (COVID-19) and cytokine release syndrome (CRS), sponsored by Zydus Lifesciences Limited. Primary endpoint: Incidence and Severity of Adverse event of ZYIL1. Started Jul 2021; status: completed.
02
Drugs
usnoflast
03
Conditions
coronavirus disease 2019 (COVID-19)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT04972188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04972188.